Phacilitate Leaders World

Conference speakers

Loading
Amol Ketkar

Amol Ketkar

VP, Cell and Gene Therapy Product Development, GSK

Amol leads Product Development for GSK’s Cell and Gene Therapy Platform CMC group. 

Amol has over 20 years of experience in Pharmaceutical and Biotech organizations.  Following successful registration of Strimvelis, Amol’s group is focusing on building an autologous cell and gene therapy platform that enables the scale up and scale out of manufacturing approaches for bringing these therapies to a wider patient population.  Prior to joining the cell and gene therapy group, Amol held positions of increasing responsibility within GSK’s Biopharm group and supported CMC development across the development lifecycle from pre-candidate selection to post commercial support.

Amol has a Bachelors degree in Pharmacy from the University of Bombay , Ph.D. in Pharmaceutics from The Ohio State University, and post-doctoral training from University of Iowa.

Sessions
Testimonials
  • Real thinking forward combining experts in the field from manufacturing, regulatory and value vision” – “great network with strong experience and sharing risks & opportunities
    Anne-Virginie Eggimann
    bluebird bio
  • Great program, great people, great venue.
    Klaus Kühlcke
    EUFETS GmbH
  • Dynamic, interesting and highly interactive event that promotes exchange and networking in highly specialized field of gene therapy.
    Nathalie Clement
    Powell Gene Therapy Center, University of Florida
  • Phacilitate provides a unique forum, bringing together research, process development, and commercial leaders on the cutting edge of cell, gene, and immunotherapy. A great conference for anyone wanting a comprehensive view of the field.
    Dr James Trager
    Dendreon
  • It was all business. I’ve never been to an event where over 80% of the conversations I had were constructive to my business objectives.
    Kurt Gielen
    Chemelot Campus B.V.
  • Great way to expand network with global experts in cell and gene therapy who are facing similar challenges.
    Steven Goodman
    GSK